Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
7 hedge funds and large institutions have $789K invested in Avenue Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
40% more funds holding
Funds holding: 5 → 7 (+2)
11% less capital invested
Capital invested by funds: $890K → $789K (-$101K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$69.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6K |
| 3 |
BlackRock
New York
|
+$4.64K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.64K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$4.64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $353K | +$18.6K | +4 | +5% |
|
|
BRWA
2
B. Riley Wealth Advisors
Boca Raton,
Florida
| $220K | -$4.64K | -1 | -2% |
|
|
FWM
3
Frontier Wealth Management
Kansas City,
Missouri
| $72K | – | – | – |
|
|
4
BlackRock
New York
| $63K | +$4.64K | +1 | +7% |
|
|
GPCM
5
Granite Point Capital Management
Boston,
Massachusetts
| $61K | +$69.6K | +15 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $18K | +$4.64K | +1 | +33% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $2K | +$4.64K | +1 | New |
|
ATXI Hedge Fund Activity: Q2 2018 in Review
7 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2018, worth a combined $789K — down 11% from $890K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ATXI positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $69.6K. The largest seller was B. Riley Wealth Advisors, cutting an estimated $4.64K.
- 7 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2018, up from 5 in Q1 2018.
- Funds reported $789K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2018, down 11% quarter-over-quarter.
- 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +2 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2018 was Granite Point Capital Management, an estimated $69.6K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2018 was B. Riley Wealth Advisors, an estimated $4.64K sold.
Based on aggregated 13F filings for Q2 2018.